Administration of BIIB028 to Subjects With Solid Tumors

Summary

Safety and Tolerability of BIIB028

Timeline

Start

2008-06

Primary completion

2011-10

Completion

2011-10

Publications

• Background Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31. doi: 10.1158/1078-0432.CCR-13-0477. Epub 2013 Jul 19.

Drugs

Indications